Published • loading... • Updated
Health Canada Prioritizes Review of FILSUVEZ for EB-Related Wounds
Summary by Patient Worthy
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
Health Canada Prioritizes Review of FILSUVEZ for EB-Related Wounds
As reported of The Manila Times, Health Canada has granted priority review to Chiesi Global Rare Diseases’ new drug submission for FILSUVEZ® (birch triterpenes) topical gel, proposed for treating wounds associated with dystrophic and junctional epidermolysis bullosa (EB) in patients aged 6 months and older. The accelerated pathway shortens the anticipated review period to roughly […]
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
